AbZelect™: Improving Cell Line Development Efficiency

02nd July 2024

Move your cell line development efficiency forwards with our AbZelect™ platform.

To progress innovative new biologic therapeutics from development to clinical phases, it is essential for developers to prove that the drug can be consistently manufactured while meeting quality standards. In the United States, this is done through the submission of an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA).

Developers face pressure from stakeholders and investors to quickly submit IND applications and show a return on investment. However, cell line development (CLD) often poses a challenge, sometimes taking up to a year to establish a stable cell line.

Why choose AbZelect™ and AbZelectPRO™?

Abzena’s AbZelect™ and AbZelectPRO™ platforms provide a solution by simplifying CLD, reducing lead candidate sequence to research cell bank generation timelines to 15 weeks, and minimizing risks for future processes to enhance efficiency.

Click here to access the info sheet to learn more about the potential benefits of this technology platform.

Abzena’s Cell Line Development Expertise

As a life science contract development and manufacturing organization (CDMO) with over
two decades of experience in cell line development, Abzena has expertise in expressing biologics ranging from antibodies, antibody fragments, fusion proteins, and vaccines.

Cell Line Development (CLD)